Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status. Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype.

Slides:

Advertisements

Similar presentations

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Advertisements

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: A guide to therapeutic decision-making in patients.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:

Supplementary Appendix Thrombotic Risk Scores % of Patients Risk Categories Low Risk (n=3491) Intermediate Risk (n=2806)

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Copyright © 2014 American Medical Association. All rights reserved.

Copyright © 2006 American Medical Association. All rights reserved.

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

From: Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome Ann Intern Med. 2014;160(4): doi: /M

Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:

Anne Masich, PharmD PGY1 Resident University of Maryland

Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;

Fig. 1. Initial coronary angiography reveals 70% narrowing of proximal LAD (A) and the stenosis is persistent after intracoronary nitrates administration.

Copyright © 2004 American Medical Association. All rights reserved.

Driving Times and Distances to Hospitals With Percutaneous Coronary Intervention in the United States by Brahmajee K. Nallamothu, Eric R. Bates, Yongfei.

Women, Bleeding, and Coronary Intervention

Proposed use of P2Y12 inhibitors

Copyright © 2009 American Medical Association. All rights reserved.

Circ Cardiovasc Interv

Case of nonobstructive coronary artery disease of left anterior descending artery (LAD) and regional LV dysfunction detected on cardiac CT with subsequent.

Spontaneous Coronary Artery Dissection

Arterioscler Thromb Vasc Biol

Circ Cardiovasc Interv

Complexities of Genetic Testing in Familial Dilated Cardiomyopathy

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Recovery of hypoplastic left heart syndrome (HLHS) mutant by ultrasound phenotyping. Recovery of hypoplastic left heart syndrome (HLHS) mutant by ultrasound.

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Imaging

11/12/2018 CYP2C19-Clopidogrel Development of these slides was supported by funding from the IGNITE Network. When using or adapting any of these slides.

11/12/2018 CYP2C19-Clopidogrel Development of these slides was supported by funding from the IGNITE Network. When using or adapting any of these slides.

Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S

Glenn N. Levine et al. JACC 2016;68:

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Glenn N. Levine et al. JACC 2016;68:

Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis Islam Y. Elgendy,

Selective left coronary angiography demonstrating normal left anterior descending (LAD) and left circumflex arteries and their branches (A). Selective.

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Nat. Rev. Cardiol. doi: /nrcardio

Peter K. Smith, MD The Journal of Thoracic and Cardiovascular Surgery

Peter K. Smith, MD The Annals of Thoracic Surgery

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Figure 2 Association between coronary artery disease polygenic risk score and the presence of migraine Results are given as odds ratios with 95% confidence.

John A. Bittl et al. JACC 2016;68:

Fig. 3. Determining factors of the proportion of class C in the hospital. (A) Relationship between the proportion of class C cases and the number of PCIs.

Baseline Characteristics

Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different.

Minimally Invasive Direct Coronary Artery Bypass Graft Surgery or Percutaneous Coronary Intervention for Proximal Left Anterior Descending Artery Stenosis:

Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S

The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing

(A) Quantitative plaque analysis of the RCA

Lee A. Fleisher et al. JACC 2014;64:e77-e137

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Forest plot illustrating the risk ratio of major bleeding

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Presentation transcript:

Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status. Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status. The frequency of alternative therapy (prasugrel or ticagrelor) use as maintenance therapy (y axis) in the strata of CYP2C19 intermediate or poor metabolizers (IM/PM) and ultrarapid, rapid, or normal metabolizers (UM/RM/NM) is presented according to the absence (No) and presence (Yes) of the following clinical factors: (A) acute coronary syndrome (ACS) indication for percutaneous coronary intervention (PCI); (B) elevated bleeding risk; (C) left anterior descending (LAD) artery stent placement. The odds ratio (OR; 95% confidence interval [CI]) for the association between presence of the clinical factor with prasugrel/ticagrelor selection within each CYP2C19 phenotype strata (IM/PM or UM/RM/NM), and the CYP2C19 phenotype*clinical factor interaction P value is provided. Craig R. Lee et al. Circ Genom Precis Med. 2018;11:e002069 Copyright © American Heart Association, Inc. All rights reserved.